VEGFR1 as a Target for Cardiovascular Gene Therapy

Area of Science:

• Cardiovascular Biology
• Molecular Medicine
• Gene Therapy

Background:

• Vascular Endothelial Growth Factor Receptor 1 (VEGFR1) is crucial for endothelial function, angiogenesis, inflammation, and cardiomyocyte survival.
• VEGFR1 exhibits both beneficial and detrimental roles in the context of cardiovascular diseases (CVDs).
• CVDs represent a significant global health burden, necessitating novel therapeutic approaches.

Purpose of the Study:

• To review the molecular biology governing VEGFR1 function.
• To elucidate VEGFR1's specific roles in the development and progression of common cardiovascular diseases.
• To discuss gene therapy strategies targeting VEGFR1 isoforms (membrane-bound and soluble sFLT1) for CVD treatment.

Main Methods:

• Literature review focusing on VEGFR1's molecular mechanisms and its involvement in cardiovascular pathologies.
• Analysis of signaling pathways mediated by VEGFR1 in various cell types relevant to CVD.
• Examination of existing and potential gene therapy approaches targeting VEGFR1 and its isoforms.

Main Results:

• VEGFR1 signaling is implicated in key pathological processes of CVDs, including aberrant angiogenesis and inflammation.
• Both membrane-bound VEGFR1 and its soluble form, sFLT1, have distinct and significant roles in cardiovascular health and disease.
• Gene therapy presents a promising avenue for modulating VEGFR1 activity to combat CVDs.

Conclusions:

• VEGFR1 is a critical mediator in cardiovascular disease pathogenesis, offering potential therapeutic targets.
• Understanding VEGFR1 signaling intricacies across different cell types is vital for effective therapeutic development.
• Targeting VEGFR1 or its isoforms via gene therapy holds significant potential for novel CVD treatments.